Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA

International Journal of Cancer

Volumn 92, Issue 3, 2001, Pages 451-456

  Morita, Tatsuo ^a   Matsuzaki, Atsushi ^a   Tokue, Akihiko ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

5 DFUR; 5 fluorouracil; Capecitabine; Renal cell carcinoma; Thymidine phosphorylase; Transfection

Indexed keywords

CAPECITABINE; COMPLEMENTARY DNA; DOXIFLURIDINE; FLUOROURACIL; LIPOFECTIN; THYMIDINE PHOSPHORYLASE;

ANIMAL CELL; ARTICLE; CELL CLONING; DNA TRANSFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, RENAL CELL; CELL SURVIVAL; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DNA, COMPLEMENTARY; DRUG SCREENING ASSAYS, ANTITUMOR; FLOXURIDINE; FLUOROURACIL; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; THYMIDINE PHOSPHORYLASE; TRANSFECTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035342546     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1212     Document Type: Article

References (38)

1. Renal cell carcinoma: Basic biology and current approaches to therapy
2. Is cytotoxic chemotherapy effective in the treatment of advanced renal cell carcinoma?
3. The role of immunotherapy for urological tumours
4. Phase II study of interferon-α and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer
5. Interleukin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell carcinoma
6. Interferon-alpha, 5-FU and prednisone in metastatic renal cell carcinoma: A phase II study
7. A phase II trial of interferon-α and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group Study
8. Treatment of renal cell carcinoma with 5-fluorouracil and alpha-interferon
9. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
10. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts
11. Identification of angiogenic activity and the cloning and the expression of platelet-derived endothelial cell growth factor
12. Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues
13. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts
14. 3-thymidine incorporation assay
15. Angiogenic factor
16. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma
17. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer
18. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma
19. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers
20. Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor
21. The activity and expression of thymidine phosphorylase in human solid tumours
22. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma
23. Expression of the angiogenic factor thymidine phosphorylase/ platelet-derived endothelial cell growth factor in human breast cancer
24. Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors
25. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil
26. Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase
27. Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA
28. Antitumor activities of a novel fluoropyrimidine, N4-pentylcarbonyl-5′-deoxy-5-fluorocytidine (capecitabine)
29. Effect of interferon on 5-fluorouracil-induced perturbations in pools of deoxynucleotide triphosphates and DNA strand breaks
30. Preclinical and clinical aspects of biomodulation of 5-fluorouracil
31. Biomodulation of 5-fluorouracil by interferon α in human renal carcinoma cells: Relation to the expression of thymidine phosphorylase
32. Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: Antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites
33. Fluorouracil and recombinant alpha-2a-interferon: An active regimen against advanced colorectal carcinoma
34. Stimulation of 5-fluorouracii metabolic activation by interferon-α in human colon carcinoma cells
35. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine
36. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts
37. Thymidine phosphporylase is angiogenic and promotes tumor growth
38. Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: In vitro and in vivo study